We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

18 hedge funds and large institutions have $56M invested in Akari Therapeutics in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

10% more capital invested

Capital invested by funds: $51M → $56M (+$5.02M)

6% more funds holding

Funds holding: 17 → 18 (+1)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
18
Holders Change
+1
Holders Change %
+5.88%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
3
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$7.28M
2
BBA
Baker Bros. Advisors
New York
+$1.62M
3
UBS Group
UBS Group
Switzerland
+$387K
4
ACP
Acuta Capital Partners
California
+$232K
5
TI
Turner Investments
Pennsylvania
+$12.9K

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management III
California
-$1.08M
2
EC
EcoR1 Capital
California
-$464K
3
RCM
RA Capital Management
Massachusetts
-$374K
4
SM
Sabby Management
Florida
-$374K
5
DCM
DAFNA Capital Management
California
-$64.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$15.5M – – –
VC
2
Vivo Capital
California
$7.12M – – –
BBA
3
Baker Bros. Advisors
New York
$6.7M +$1.62M +126 +25%
NMC
4
NEA Management Company
Maryland
$6.1M +$7.28M +565 New
VMI
5
VHCP Management II
New York
$4.98M – – –
RCM
6
RA Capital Management
Massachusetts
$3.16M -$374K -29 -9%
QF
7
QVT Financial
New York
$2.91M – – –
FCMI
8
Foresite Capital Management III
California
$2.66M -$1.08M -84 -25%
VM
9
VHCP Management
New York
$2.14M – – –
BC
10
Boxer Capital
California
$1.89M – – –
EC
11
EcoR1 Capital
California
$856K -$464K -36 -31%
GTC
12
Ghost Tree Capital
New York
$629K – – –
ACP
13
Acuta Capital Partners
California
$446K +$232K +18 +78%
UBS Group
14
UBS Group
Switzerland
$345K +$387K +30 +1,500%
Deutsche Bank
15
Deutsche Bank
Germany
$315K – – –
SM
16
Sabby Management
Florida
$235K -$374K -29 -57%
TI
17
Turner Investments
Pennsylvania
$13K +$12.9K +1 New
DCM
18
DAFNA Capital Management
California
$6K -$64.5K -5 -83%
Morgan Stanley
19
Morgan Stanley
New York
$5K -$25.8K -2 Closed
TRCT
20
Tower Research Capital (TRC)
New York
$4K – – –

AKTX Hedge Fund Activity: Q2 2016 in Review

18 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2016, worth a combined $56M — up 9.8% from $51M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new AKTX positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $7.28M. The largest seller was Foresite Capital Management III, cutting an estimated $1.08M.

  • 18 institutional investors held Akari Therapeutics (AKTX) as of Q2 2016, up from 17 in Q1 2016.
  • Funds reported $56M of Akari Therapeutics stock for Q2 2016, up 9.8% quarter-over-quarter.
  • 2 funds opened new Akari Therapeutics positions in Q2 2016 and 1 closed out, a net change of +1 holder.
  • The largest Akari Therapeutics buyer in Q2 2016 was NEA Management Company, an estimated $7.28M added.
  • The largest Akari Therapeutics seller in Q2 2016 was Foresite Capital Management III, an estimated $1.08M sold.

Based on aggregated 13F filings for Q2 2016.